Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Rheumatology

Current Standard of Care Treatments for Systemic Sclerosis

At a Glance

Modern systemic sclerosis treatment uses a personalized approach targeting specific organ involvement. Core therapies include immunosuppressants, targeted biologics, and antifibrotics, while extreme caution must be taken with corticosteroids due to the risk of severe kidney complications.

Treatment for systemic sclerosis (SSc) has evolved significantly, moving toward a “precision medicine” approach. According to the 2023 EULAR (European Alliance of Associations for Rheumatology) recommendations, the goal of modern therapy is to target specific organ involvement early to prevent long-term damage [1][2]. Because SSc is so variable, your treatment plan will be uniquely tailored to your symptoms and antibody profile [2].

A Critical Warning: Corticosteroids

While corticosteroids (like prednisone) are commonly used in other autoimmune diseases, they must be used with extreme caution in systemic sclerosis.

  • The Risk: High-to-medium doses of corticosteroids (often defined as more than 15mg of prednisone per day) are strongly associated with Scleroderma Renal Crisis (SRC) [3][4].
  • What is SRC? This is a life-threatening complication where blood pressure spikes suddenly, potentially leading to rapid kidney failure [5].
  • The Recommendation: If your doctor prescribes steroids, they should be used at the lowest possible dose for the shortest time, with frequent—often daily—monitoring of your blood pressure [6][7].

Core Treatment Strategies

Doctors group treatments by their main goal: calming the immune system, slowing scarring, or improving blood flow.

1. Immunosuppression (Calming the Immune System)

These medications aim to stop the immune system from attacking your tissues.

  • Mycophenolate Mofetil (MMF): Often considered a first-line therapy, especially for patients with lung involvement (SSc-ILD). It helps stabilize lung function over time [8][9].
  • Cyclophosphamide: A more intensive immunosuppressant typically reserved for severe or rapidly progressing lung disease [10].
  • Important Safety Warning: Both MMF and Cyclophosphamide are highly teratogenic, meaning they can cause severe birth defects. If you are of childbearing age, strict contraception is absolutely required while taking these medications [1].

2. Biologics (Targeted Immune Therapy)

These are newer, “smarter” drugs that target specific proteins in the immune system.

  • Rituximab: A biologic that targets B-cells. Recent research shows it can be effective for both skin thickening and lung disease [11][12].
  • Tocilizumab: This targets a protein called IL-6 and has been approved to help slow the decline of lung function in SSc [13].

3. Antifibrotics (Slowing Scarring)

  • Nintedanib: This is a specialized medication that blocks the pathways that lead to scarring (fibrosis). It is specifically used to slow the progression of interstitial lung disease [14][15]. It is often used in combination with MMF [16].

Managing Vascular Symptoms (Blood Flow)

Improving blood flow is essential for managing Raynaud’s phenomenon and preventing digital ulcers (painful sores on the fingertips) [17].

  • First-line: Calcium Channel Blockers (like nifedipine or amlodipine) help relax and open blood vessels [18][19].
  • Second-line: PDE-5 Inhibitors (like sildenafil) or Endothelin Receptor Antagonists (like bosentan) can be used if ulcers persist or Raynaud’s is severe [20]. Importantly, these same medications are the primary, life-saving therapies used to treat Pulmonary Arterial Hypertension (PAH) [21].
  • Emergency/Severe: For very severe blood flow issues, doctors may use intravenous prostanoids (like iloprost) to keep the blood moving and prevent tissue damage [22][23].

Looking Ahead

For the most severe, rapidly progressing cases, Autologous Hematopoietic Stem Cell Transplantation (HSCT) may be considered. This intensive procedure “resets” the immune system and has shown high success in carefully selected patients [24][25]. Always discuss the balance of risks and benefits for any treatment with your rheumatology team [1].

Common questions in this guide

Are corticosteroids safe to take for systemic sclerosis?
High-to-medium doses of corticosteroids, such as prednisone, can trigger a life-threatening complication called Scleroderma Renal Crisis. This crisis causes a sudden, dangerous spike in blood pressure that can lead to rapid kidney failure.
What medications are used to treat lung involvement in scleroderma?
Doctors frequently prescribe immunosuppressants like mycophenolate mofetil (MMF) to stabilize lung function. An antifibrotic medication called nintedanib is also commonly used to slow down lung scarring associated with the disease.
How do doctors treat painful digital ulcers and severe Raynaud's?
First-line treatments include calcium channel blockers to help relax blood vessels and improve circulation. If ulcers persist, doctors may prescribe PDE-5 inhibitors like sildenafil or endothelin receptor antagonists to boost blood flow to the fingers.
What is the role of biologics in treating systemic sclerosis?
Biologics are targeted therapies that focus on specific proteins driving the immune system's attack. Medications like rituximab and tocilizumab can help manage skin thickening and slow the decline of lung function in systemic sclerosis.
Is stem cell transplant a treatment option for scleroderma?
Autologous Hematopoietic Stem Cell Transplantation (HSCT) can be an option for severe, rapidly progressing systemic sclerosis. This intensive procedure aims to reset the immune system, but it carries significant risks that require careful consideration.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Are any of the medications I am currently taking, such as corticosteroids, putting me at risk for a scleroderma renal crisis?
  2. 2.Given my specific antibody profile and symptoms, should we start with an immunosuppressant like mycophenolate mofetil or a biologic?
  3. 3.Do I have enough lung involvement to justify adding an antifibrotic like nintedanib to my treatment plan?
  4. 4.What is our 'rescue plan' if my Raynaud's phenomenon worsens or if I develop a painful digital ulcer?
  5. 5.If we decide to use a biologic like rituximab or tocilizumab, what is the monitoring schedule for potential side effects?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (25)
  1. 1

    Results from the international collaborative systematic literature review informing the 2023 EULAR recommendations for the treatment of systemic sclerosis.

    Lescoat A, Bertoldo E, Čolić J, et al.

    Annals of the rheumatic diseases 2024; doi:10.1136/ard-2024-226429.

    PMID: 39515834
  2. 2

    2023 Brazilian Society of Rheumatology guidelines for the treatment of systemic sclerosis.

    Kayser C, de Oliveira Delgado SM, Zimmermann AF, et al.

    Advances in rheumatology (London, England) 2024; (64(1)):52 doi:10.1186/s42358-024-00392-w.

    PMID: 38987832
  3. 3

    Refractory scleroderma renal crisis precipitated after high-dose oral corticosteroids and concurrent intravitreal injection of bevacizumab.

    Hanna RM, Abdelnour L, Zuckerman JE, et al.

    SAGE open medical case reports 2020; (8()):2050313X20952650 doi:10.1177/2050313X20952650.

    PMID: 32913652
  4. 4

    Renal Involvement in Systemic Sclerosis: An Update.

    Chrabaszcz M, Małyszko J, Sikora M, et al.

    Kidney & blood pressure research 2020; (45(4)):532-548 doi:10.1159/000507886.

    PMID: 32521536
  5. 5

    Scleroderma Renal Crisis in a Normotensive Patient.

    Asamoah-Odei E

    Kidney international reports 2016; (1(4)):311-315 doi:10.1016/j.ekir.2016.07.005.

    PMID: 29318207
  6. 6

    Clinical trial protocol: PRednisolone in early diffuse cutaneous Systemic Sclerosis (PRedSS).

    Herrick AL, Griffiths-Jones DJ, Ryder WD, et al.

    Journal of scleroderma and related disorders 2021; (6(2)):146-153 doi:10.1177/2397198320957552.

    PMID: 34222671
  7. 7

    Thrombotic Microangiopathy and Multiple Organ Failure in Scleroderma Renal Crisis: A Case Report.

    Aterini L, Gallo M, Vadalà B, Aterini S

    Cureus 2023; (15(8)):e44322 doi:10.7759/cureus.44322.

    PMID: 37779794
  8. 8

    Systemic sclerosis-associated interstitial lung disease: How to manage in 2024?

    Bautista-Sanchez R, Khanna D

    Rheumatology and immunology research 2024; (5(3)):157-165 doi:10.2478/rir-2024-0022.

    PMID: 39439972
  9. 9

    Review: Frontiers of Antifibrotic Therapy in Systemic Sclerosis.

    Distler JH, Feghali-Bostwick C, Soare A, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2017; (69(2)):257-267 doi:10.1002/art.39865.

    PMID: 27636741
  10. 10

    [Treatment of systemic sclerosis-associated interstitial lung disease].

    Prasse A, Bonella F, Müller-Ladner U, et al.

    Zeitschrift fur Rheumatologie 2020; (79(3)):294-303 doi:10.1007/s00393-019-00724-y.

    PMID: 31754786
  11. 11

    Real-world treatment for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: information from a Japanese hospital claims database.

    Funatogawa T, Mii K, Kojima K, et al.

    Modern rheumatology 2025; (36(1)):39-48 doi:10.1093/mr/roaf082.

    PMID: 40928153
  12. 12

    Rituximab in systemic sclerosis-associated interstitial lung disease: A systematic review and meta-analysis.

    Jang JH, Her M, Oh JH, et al.

    Science progress 2025; (108(2)):368504251333912 doi:10.1177/00368504251333912.

    PMID: 40232230
  13. 13

    Rituximab on lung, skin, and joint involvement in patients with systemic sclerosis: A case series study and review of the literature.

    Yarkan Tuğsal H, Zengin B, Kenar G, et al.

    International journal of rheumatic diseases 2022; (25(7)):755-768 doi:10.1111/1756-185X.14333.

    PMID: 35535670
  14. 14

    The adoption of nintedanib in systemic sclerosis: the SENSCIS study.

    Bruni T, Varone F

    Breathe (Sheffield, England) 2020; (16(2)):200005 doi:10.1183/20734735.0005-2020.

    PMID: 32665787
  15. 15

    Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease.

    Yamasaki Y, Kuwana M

    Expert review of clinical immunology 2020; (16(6)):547-560 doi:10.1080/1744666X.2020.1777857.

    PMID: 32506975
  16. 16

    The fibrosis puzzle of systemic sclerosis-associated ILD and the quest for targeted interventions.

    Doskaliuk B, Zaiats L, Sahan N, et al.

    Therapeutic advances in respiratory disease 2025; (19()):17534666251366023 doi:10.1177/17534666251366023.

    PMID: 40817801
  17. 17

    Treatment recommendations for the systemic pharmacological treatment of systemic sclerosis digital ulcers: Results from the World Scleroderma Foundation Ad Hoc Committee.

    Maltez N, Ross L, Baron M, et al.

    Journal of scleroderma and related disorders 2025; 23971983251340559 doi:10.1177/23971983251340559.

    PMID: 40852405
  18. 18

    New horizons in systemic sclerosis treatment: advances and emerging therapies in 2025.

    Sieiro Santos C, Del Galdo F

    RMD open 2025; (11(3)) doi:10.1136/rmdopen-2025-005776.

    PMID: 40592721
  19. 19

    Raynaud's phenomenon associated with psoriatic arthritis.

    Che Rahim MJ, Lim JA, Wan Ghazali WS

    BMJ case reports 2024; (17(3)) doi:10.1136/bcr-2023-258215.

    PMID: 38442964
  20. 20

    Combination therapy with bosentan and sildenafil for refractory digital ulcers and Raynaud's phenomenon in a 30-year-old woman with systemic sclerosis: Case report and literature review.

    Rademacher JG, Wincup C, Tampe B, Korsten P

    Journal of scleroderma and related disorders 2020; (5(2)):159-164 doi:10.1177/2397198319876738.

    PMID: 35382024
  21. 21

    EULAR recommendations for the treatment of systemic sclerosis: 2023 update.

    Del Galdo F, Lescoat A, Conaghan PG, et al.

    Annals of the rheumatic diseases 2025; (84(1)):29-40 doi:10.1136/ard-2024-226430.

    PMID: 39874231
  22. 22

    Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study.

    Denton CP, Hachulla É, Riemekasten G, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2017; (69(12)):2370-2379 doi:10.1002/art.40242.

    PMID: 29193819
  23. 23

    Management of Raynaud's phenomenon in systemic sclerosis-a practical approach.

    Fernández-Codina A, Cañas-Ruano E, Pope JE

    Journal of scleroderma and related disorders 2019; (4(2)):102-110 doi:10.1177/2397198318823951.

    PMID: 35382396
  24. 24

    [The arguments favoring autologous haematopoietic stem cell transplantation in systemic scleroderma].

    Pugnet G

    La Revue de medecine interne 2024; (45(2)):104-108 doi:10.1016/j.revmed.2024.01.003.

    PMID: 38267322
  25. 25

    Hematopoietic stem cell transplantation for systemic sclerosis: Brazilian experience.

    Henrique-Neto Á, Vasconcelos MYK, Dias JBE, et al.

    Advances in rheumatology (London, England) 2021; (61(1)):9 doi:10.1186/s42358-021-00166-8.

    PMID: 33549135

This page provides educational information about current treatments for systemic sclerosis. It does not replace professional medical advice; always consult your rheumatologist before changing your treatment plan or starting new medications.

Get notified when new evidence is published on Systemic sclerosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.